Elbasvir/Grazoprevir Hydrate/Uprifosbuvir

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameElbasvir/Grazoprevir Hydrate/Uprifosbuvir
Drug Alias Name艾尔巴韦/格拉瑞韦/UprifosbuvirUprifosbuvir/Elbasvir/GrazoprevirGrazoprevir/Uprifosbuvir/ElbasvirElbasvir/grazoprevir/MK-3682Elbasvir/Grazoprevir/Uprifosbuvir +[7] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives
Mechanisms of ActionNonstructural protein 5A inhibitorsHepatitis C virus serine protease, NS3/NS4A inhibitorsHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymeraseNonstructural protein 5AHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes UprifosbuvirElbasvirGrazoprevir Hydrate
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Sharp & Dohme Corp
Active IndicationsN/A
Inactive IndicationsHepatitis C

Other Information

ATC CodeN/A
Related LinksN/A